Podcasts about treatment decisions

In this podcast, 2 leading haematologists discuss the unmet needs in multiple myeloma in the second-line setting and beyond, considerations for treatment decisions, and the evolving treatment landscape with a focus on B-cell maturation antigen-targeted bispecific antibodies, a rapidly advancing class of treatments in this setting. This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the Advances in Therapy website and by using this link: https://link.springer.com/article/10.1007/s12325-026-03715-z. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZBS865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 29, 2027.Personalized Interventions in Neuroendocrine Tumors: Applying the Latest Systemic Therapy Evidence to Guide Treatment Decisions in Community-Based Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Neuroendocrine Cancer Awareness Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Exelixis, Inc. and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZBS865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 29, 2027.Personalized Interventions in Neuroendocrine Tumors: Applying the Latest Systemic Therapy Evidence to Guide Treatment Decisions in Community-Based Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Neuroendocrine Cancer Awareness Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Exelixis, Inc. and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZBS865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 29, 2027.Personalized Interventions in Neuroendocrine Tumors: Applying the Latest Systemic Therapy Evidence to Guide Treatment Decisions in Community-Based Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Neuroendocrine Cancer Awareness Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Exelixis, Inc. and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZBS865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 29, 2027.Personalized Interventions in Neuroendocrine Tumors: Applying the Latest Systemic Therapy Evidence to Guide Treatment Decisions in Community-Based Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Neuroendocrine Cancer Awareness Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Exelixis, Inc. and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZBS865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 29, 2027.Personalized Interventions in Neuroendocrine Tumors: Applying the Latest Systemic Therapy Evidence to Guide Treatment Decisions in Community-Based Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Neuroendocrine Cancer Awareness Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Exelixis, Inc. and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZBS865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 29, 2027.Personalized Interventions in Neuroendocrine Tumors: Applying the Latest Systemic Therapy Evidence to Guide Treatment Decisions in Community-Based Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Neuroendocrine Cancer Awareness Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Exelixis, Inc. and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Bilal Siddiqui, MD Long-term management of metastatic castration-sensitive prostate cancer (mCSPC) goes beyond selecting an effective therapy—it also requires careful consideration of tolerability, drug interactions, and treatment access. Balancing these factors can help clinicians personalize care while supporting adherence and quality of life over time. Joining Dr. Charles Turck to share practical strategies for navigating these decisions and tailoring treatment to each patient's unique needs is Dr. Bilal Siddiqui. He's an Assistant Professor in the Department of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston.

What stands between a patient with geographic atrophy and consistent, effective treatment? And how do clinicians bridge that gap? In episode 3 of the GA in Practice miniseries on New Retina Radio, moderator Geeta Lalwani, MD, and panelists Murtaza Adam, MD, and Carl Danzig, MD, address injection burden, insurance hurdles, and the role of patient education tools in supporting adherence. The group also weighs the potential for AI to guide treatment decisions and track progression, then works through a hypothetical case of an 82-year-old caregiver with bilateral diffuse trickling GA who is not yet motivated to pursue treatment.

Which imaging biomarkers matter most at diagnosis of GA, and how should they shape the decision to treat? In episode 1 of the GA in Practice miniseries on New Retina Radio, moderator Geeta Lalwani, MD, and panelists Murtaza Adam, MD, and Carl Danzig, MD, review the practical role of fundus autofluorescence and OCT in identifying high-risk GA, discuss ellipsoid zone integrity as an emerging endpoint, and work through a hypothetical case of an active, motivated patient with bilateral extrafoveal GA and good vision to explore how lifestyle, lesion characteristics, and patient education factor into early treatment decisions.

Host: Alexandria May, PharmD, BCPS Guest: Neil M. Iyengar, MD As first-line treatment options for metastatic triple-negative breast cancer continue to expand, emerging evidence and guideline updates are reshaping treatment selection. In this expert-led discussion, Dr. Alexandria May and Dr. Neil Iyengar review the growing role of biomarker-driven decision-making and examine how data from ASCENT-03, ASCENT-04, and TROPION-Breast02 are influencing preferred treatment approaches. Dr. Iyengar is the Director of the Cancer Survivorship Program and Co-Director of the Breast Medical Oncology Program at Winship Cancer Institute at Emory University.

CME credits: 1.00 Valid until: 07-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/egfr-mutated-nsclc-with-brain-metastases-navigating-adc-treatment-decisions/56521/ What are the key considerations when managing brain metastases in patients with breast and lung cancer? This online CME activity uses case-based discussion to examine the epidemiology and clinical burden of central nervous system (CNS) involvement and how brain metastases influence prognosis, therapeutic priorities, and treatment sequencing. Participants will evaluate emerging evidence on the intracranial activity of systemic therapies and consider how tumor biology, symptom burden, and prior treatment inform therapy selection. This activity also highlights multidisciplinary collaboration among medical oncology, radiation oncology, and neuro-oncology to support coordinated care including management of CNS-related toxicities and optimize outcomes for patients with brain metastases from breast or lung cancer.

“In breast cancer now, all of our treatment for hormone receptor–positive metastatic disease is a bit of a moving target because of new therapies that are available,” explains Hope S. Rugo, MD, division chief of breast medical oncology and the Women's Cancers Program director at the City of Hope Comprehensive Cancer Center in Duarte, California. She discusses the “ever-changing” landscape involving the PI3 kinase/AKT/mTOR pathway with Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at Cedars-Sinai Cancer in Los Angeles. Dr. Rugo details key considerations that she uses for decision making in practice. “And I think we just want to be cautious about toxicity for these patients and really know that we're benefiting them, rather than using up treatments,” she explains.  

Dr. Dipen Maun shares the basics of colorectal cancer, what happens while you're sedated during a colonoscopy, and colorectal cancer treatment options.

Dr Gabriel Mannis from Stanford University and Dr Gail Roboz from Weill Cornell Medicine discussed the evolving treatment landscape for relapsed/refractory NPM1-mutant acute myeloid leukemia (AML). The conversation highlighted the dramatic transformation of relapsed/refractory AML management from a space where "drugs went to die" to one with multiple targeted therapeutic options.Dr Roboz emphasized the importance of comprehensive mutational reassessment at relapse, as co-mutation profiles can change from initial diagnosis. She distinguished between mutational profiling for treatment selection versus minimal residual disease (MRD) monitoring, noting that NPM1 was previously considered undruggable but now has two FDA-approved menin inhibitors: revumenib and ziftomenib.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TPK865. CME credit will be available until March 11, 2027.Disease and Disability Progression in Relapsing MS: Unpacking Efficacy Data to Advance Treatment DecisionsThe University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The University of Cincinnati and PVI, PeerView Institute for Medical Education, are both accredited by the ACCME to provide continuing medical education for physicians and have collaborated to design and execute this activity. For accreditation purposes, the University of Cincinnati is responsible for certification and documentation of attendance for this activity.SupportThis independent Satellite Symposium is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TPK865. CME credit will be available until March 11, 2027.Disease and Disability Progression in Relapsing MS: Unpacking Efficacy Data to Advance Treatment DecisionsThe University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The University of Cincinnati and PVI, PeerView Institute for Medical Education, are both accredited by the ACCME to provide continuing medical education for physicians and have collaborated to design and execute this activity. For accreditation purposes, the University of Cincinnati is responsible for certification and documentation of attendance for this activity.SupportThis independent Satellite Symposium is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TPK865. CME credit will be available until March 11, 2027.Disease and Disability Progression in Relapsing MS: Unpacking Efficacy Data to Advance Treatment DecisionsThe University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The University of Cincinnati and PVI, PeerView Institute for Medical Education, are both accredited by the ACCME to provide continuing medical education for physicians and have collaborated to design and execute this activity. For accreditation purposes, the University of Cincinnati is responsible for certification and documentation of attendance for this activity.SupportThis independent Satellite Symposium is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TPK865. CME credit will be available until March 11, 2027.Disease and Disability Progression in Relapsing MS: Unpacking Efficacy Data to Advance Treatment DecisionsThe University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The University of Cincinnati and PVI, PeerView Institute for Medical Education, are both accredited by the ACCME to provide continuing medical education for physicians and have collaborated to design and execute this activity. For accreditation purposes, the University of Cincinnati is responsible for certification and documentation of attendance for this activity.SupportThis independent Satellite Symposium is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TPK865. CME credit will be available until March 11, 2027.Disease and Disability Progression in Relapsing MS: Unpacking Efficacy Data to Advance Treatment DecisionsThe University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The University of Cincinnati and PVI, PeerView Institute for Medical Education, are both accredited by the ACCME to provide continuing medical education for physicians and have collaborated to design and execute this activity. For accreditation purposes, the University of Cincinnati is responsible for certification and documentation of attendance for this activity.SupportThis independent Satellite Symposium is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TPK865. CME credit will be available until March 11, 2027.Disease and Disability Progression in Relapsing MS: Unpacking Efficacy Data to Advance Treatment DecisionsThe University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The University of Cincinnati and PVI, PeerView Institute for Medical Education, are both accredited by the ACCME to provide continuing medical education for physicians and have collaborated to design and execute this activity. For accreditation purposes, the University of Cincinnati is responsible for certification and documentation of attendance for this activity.SupportThis independent Satellite Symposium is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TPK865. CME credit will be available until March 11, 2027.Disease and Disability Progression in Relapsing MS: Unpacking Efficacy Data to Advance Treatment DecisionsThe University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The University of Cincinnati and PVI, PeerView Institute for Medical Education, are both accredited by the ACCME to provide continuing medical education for physicians and have collaborated to design and execute this activity. For accreditation purposes, the University of Cincinnati is responsible for certification and documentation of attendance for this activity.SupportThis independent Satellite Symposium is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TPK865. CME credit will be available until March 11, 2027.Disease and Disability Progression in Relapsing MS: Unpacking Efficacy Data to Advance Treatment DecisionsThe University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The University of Cincinnati and PVI, PeerView Institute for Medical Education, are both accredited by the ACCME to provide continuing medical education for physicians and have collaborated to design and execute this activity. For accreditation purposes, the University of Cincinnati is responsible for certification and documentation of attendance for this activity.SupportThis independent Satellite Symposium is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

If cancer treatment pushed you into menopause, you may be sitting there scratching your head, wondering what on earth is happening to your body, why no one warned you, and where you're supposed to turn for support. That's exactly where Holly found herself.In this episode of The Menopause and Cancer Podcast, I'm joined by Holly Adcock, who first had vicious night sweats during chemotherapy and later came into our community through one of our in-person Menopause and Cancer workshops. Holly shares her lived experience of navigating menopause after cancer while facing complex and ongoing treatment decisions about her own care — a powerful reminder that menopause after cancer is rarely linear.Instead, it's a wriggly road. One that often feels like an uphill hike, with twists, setbacks, and moments where you're not quite sure which way to turn next.I hope this conversation will make you feel like someone is walking alongside you, hand in hand, reminding you that you are not broken, you are not failing — and you are not alone on this hike.If you are like me, then maybe putting one foot in front of the other is what is good for you too - below are the links to our walking challenges - come walk with me.The links are here:BOOST30: https://fundraiseformenopauseandcancer.raiselysite.com/Boost30GET INVOLVED: https://fundraiseformenopauseandcancer.raiselysite.com/Episode Highlights:00:00 Intro07:05 Osteoporosis, Endocrine Therapy, and Cancer12:43 "Facing Chemotherapy Expectations"16:25 Understanding Menopause and Its Symptoms20:01 "Unheard Challenges of Menopause"23:32 "Revived by Friendship and Support"30:22 "Life-Changing Career Redirection"31:31 "Embracing Positivity Through Reframing"40:08 "Surgical Menopause Decision Struggle"Connect with Holly:https://www.menopausecare.co.uk/associate-holly-adcockConnect with us:For more information and resources visit our website: www.menopauseandcancer.org Or follow us on Instagram @menopause_and_cancerJoin our Facebook group: www.facebook.com/groups/menopauseandcancerchathub

In today's episode, the discussion features Adam Fox, MD, an assistant professor in the Department of Medicine at the College of Medicine at the Medical University of South Carolina in Charleston, and Cynthia A. Schandl, MD, PhD, medical director of clinical laboratories and director of the Division of Clinical Pathology in the College of Medicine at the Medical University of South Carolina, who examined the expanding role of biomarker testing and genomic profiling in non–small cell lung cancer (NSCLC) across disease stages

Shared decision-making isn't just a buzzword—it's the key to better adherence, fewer exacerbations, and improved quality of life for your patients. Credit available for this activity expires: [01/30/27] Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/empowering-choices-moderate-severe-asthma-partnering-2026a10001d4?ecd=bdc_podcast_libsyn_mscpedu

See how top sleep specialists turn evidence into action with real-world cases that reveal smarter, patient-centered treatment strategies. Credit available for this activity expires: 12/22/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/case-review-narcolepsy-and-idiopathic-hypersomnia-2025a1000zqa?ecd=bdc_podcast_libsyn_mscpedu

Blood is a rich source for biomarker development, and CTCs are increasingly proving themselves to be valuable in cancer prognosis and treatment prediction. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Craig Eagle, Chief Medical Officer of Guardant Health, a precision medicine company that offers blood tests to inform cancer treatment decisions. Eagle discusses Guardant's participation in the National Cancer Institute's Vanguard Study, as well as screening, recurrence monitoring, and therapy selection focused on conquering cancer with data, with examples especially in the colorectal cancer space. You can listen to episode 229 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

CME credits: 0.25 Valid until: 30-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/are-all-vmat2s-the-same-data-driven-treatment-decisions-for-tardive-dyskinesia/36174/ Tardive Dyskinesia (TD) is an involuntary movement disorder that can develop as a side effect of taking antipsychotic and other medications. Currently there are 2 FDA approved VMAT2 inhibitors for treating TD. Join Drs. Cristoph U. Correll and Jonathan M. Meyer for this expert discussion on the most recent data presented at the Psych Congress 2025 in San Diego on VMAT2 inhibitors for the treatment of TD.=

Financial Toxicities in Breast Cancer: How Costs Impact Treatment Decisions with guest Dr. Rachel Greenup October 5, 2025 Yale Cancer Center visit: https://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

Financial Toxicities in Breast Cancer: How Costs Impact Treatment Decisions with guest Dr. Rachel Greenup October 5, 2025 Yale Cancer Center visit: https://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

Artificial Intelligence (AI) and Lung Cancer Treatment Decisions by IASLC

Artificial Intelligence (AI) and Lung Cancer Treatment Decisions by IASLC

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH information, and to apply for credit, please visit us at PeerView.com/JWX865. CME/EBAH credit will be available until July 22, 2026.The Second Coming of Finite Therapy in CLL: Making Informed Treatment Decisions With Newer, Time-Limited BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH information, and to apply for credit, please visit us at PeerView.com/JWX865. CME/EBAH credit will be available until July 22, 2026.The Second Coming of Finite Therapy in CLL: Making Informed Treatment Decisions With Newer, Time-Limited BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH information, and to apply for credit, please visit us at PeerView.com/JWX865. CME/EBAH credit will be available until July 22, 2026.The Second Coming of Finite Therapy in CLL: Making Informed Treatment Decisions With Newer, Time-Limited BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH information, and to apply for credit, please visit us at PeerView.com/JWX865. CME/EBAH credit will be available until July 22, 2026.The Second Coming of Finite Therapy in CLL: Making Informed Treatment Decisions With Newer, Time-Limited BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH information, and to apply for credit, please visit us at PeerView.com/JWX865. CME/EBAH credit will be available until July 22, 2026.The Second Coming of Finite Therapy in CLL: Making Informed Treatment Decisions With Newer, Time-Limited BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JCA865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until May 26, 2026.AD-SAFE: An Initiative to Build Understanding of ARIA and Skills Needed to Guide Treatment Decisions and Support Rapid Recognition and Response in Radiology In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JCA865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until May 26, 2026.AD-SAFE: An Initiative to Build Understanding of ARIA and Skills Needed to Guide Treatment Decisions and Support Rapid Recognition and Response in Radiology In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JCA865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until May 26, 2026.AD-SAFE: An Initiative to Build Understanding of ARIA and Skills Needed to Guide Treatment Decisions and Support Rapid Recognition and Response in Radiology In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JCA865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until May 26, 2026.AD-SAFE: An Initiative to Build Understanding of ARIA and Skills Needed to Guide Treatment Decisions and Support Rapid Recognition and Response in Radiology In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/SDR865. CME credit will be available until May 20, 2026.Adopting Innovation in Bladder Cancer: Aligning the Evidence on Antibody–Drug Conjugates to Inform Treatment Decisions In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Astellas and Pfizer, IncDisclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/SDR865. CME credit will be available until May 20, 2026.Adopting Innovation in Bladder Cancer: Aligning the Evidence on Antibody–Drug Conjugates to Inform Treatment Decisions In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Astellas and Pfizer, IncDisclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/SDR865. CME credit will be available until May 20, 2026.Adopting Innovation in Bladder Cancer: Aligning the Evidence on Antibody–Drug Conjugates to Inform Treatment Decisions In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Astellas and Pfizer, IncDisclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SUC865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until May 18, 2026.AD-SAFE: An Initiative to Build Understanding of ARIA and Skills Needed to Guide Treatment Decisions in Primary Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SUC865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until May 18, 2026.AD-SAFE: An Initiative to Build Understanding of ARIA and Skills Needed to Guide Treatment Decisions in Primary Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SUC865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until May 18, 2026.AD-SAFE: An Initiative to Build Understanding of ARIA and Skills Needed to Guide Treatment Decisions in Primary Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SUC865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until May 18, 2026.AD-SAFE: An Initiative to Build Understanding of ARIA and Skills Needed to Guide Treatment Decisions in Primary Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

Investing continues to evolve and a new way some fiduciary financial advisors are charging for services could save you money. Know your options to make an informed choice for financial services. Also, before you sign up for expensive dental work, think twice & take Clark's advice. Flat Fee Financial Advisors: Segment 1 Ask Clark: Segment 2 Wisdom Teeth- AVOID Unnecessary Dental Work: Segment 3 Ask Clark: Segment 4 Mentioned on the show: Flat Fee Shops Attempt to Shake Up Financial Advising Advice-Only Network // Flat Fee Advisors 3 Places You Should Never Invest Your Money What Is a Fiduciary Financial Advisor and Do I Need One? How To Find and Choose a Financial Advisor What Is an HSA Account and How Does It Work? Target Date Funds: Clark's Favorite Retirement Investment How to Advocate for Yourself at the Dentist How getting a second opinion can stop you being ripped off — The Conversation Yes, your smart TV is spying on you – Here's how to stop it GM Stops Selling Driving Data to Insurance Companies How to Buy a New Car in 5 Steps Thank you for listening today, Clarkies! If you want to be part of our “Clarkie” segment, call 404-981-2071 to leave a comment or story. We may play it during a future episode! Clark.com resources Episode transcripts Community.Clark.com Clark.com daily money newsletter Consumer Action Center Free Helpline: 636-492-5275 Learn more about your ad choices: megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices